Please provide your email address to receive an email when new articles are posted on . Data presented at the International Congress on Schizophrenia Research indicated a higher dose of Aristada may ...
Alkermes announced positive top-line results from its pharmacokinetics trial of Aristada (aripiprazole lauroxil extended-release injectable suspension). Alkermes announced positive top-line results ...
About ARISTADA® ARISTADA is an injectable atypical antipsychotic with one-month and six-week dosing options for the treatment of schizophrenia. ARISTADA is administered by a healthcare professional.
The new dosing option allows patients with schizophrenia to treat their symptoms with just 6 injections per year Alkermes announced that the Food and Drug Administration (FDA) has approved a 2-month ...
About ARISTADA® ARISTADA is an injectable atypical antipsychotic with one-month and six-week dosing options for the treatment of schizophrenia. ARISTADA is administered by a healthcare professional.
The FDA approval of Aristada for use every two months provides more dosing flexibility and may encourage more doctors to prescribe it. Nowadays, Alkermes has focused a lot of its attention on crafting ...
— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders — ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA today approved 2-month Aristada, an ...
Overall, ARISTADA will be priced comparable to other products in this class, but given the unique features of ARISTADA such as the availability of three different doses and the six-week dosing ...
The US FDA has approved Alkermes' long-acting injectable (LAI) schizophrenia drug Aristada, the first drug of its type that can be administered at four- or six-weekly intervals. Alkermes specialises ...
The FDA (Food and Drug Administration) approved Aristada (Aripiprazole Lauroxil) partly on account of the drug’s clinical trials, which proved that patients using the treatment saw reductions in the ...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA™ (aripiprazole lauroxil) extended-release injectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results